EicOsis
EicOsis is developing a new approach to treat pain and inflammation by inhibiting the soluble Epoxide Hydrolase (sEH), a key regulatory enzyme. Inhibiting sEH increases the levels of naturally occurring anti-inflammatory and pain-relieving compounds. Its first drug candidate is currently undergoing Phase 1 human clinical trials.
Contact Email:
Website:
https://www.eicosis.com/
City, State – Congressional District:
Davis,
CA
–
4
Technology:
Drug
Funding:
Drug Abuse (NIDA),
Environmental Health (NIEHS),
Heart, Lung, and Blood (NHLBI),
Neurological Disorders and Stroke (NINDS)
NIH Projects:
NIH RePorter for
EicOsis
Sponsored Event(s):
Life Sciences Summit | 2023
